Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 outpatients meta-analysis

BLAZE-1 phase 3 (combo), 2021
 
NCT04427501
RCTbamlanivimab/etesevimabplaceboCOVID 19 outpatientssome concern
518/517 suggested
  • suggested 71 % decrease in hospitalization or death (PE) with a moderate degree of certainty due to some concern in risk of bias
  • suggested 95 % decrease in deaths with a moderate degree of certainty due to some concern in risk of bias
COMET-ICE, 2021
 
NCT04545060
RCTsotrovimab (Xevudy; VIR-7831)placeboCOVID 19 outpatientslow
528/529 conclusif
  • demonstrated 79 % decrease in hospitalization or death (PE) with a high degree of certainty due to low risk of bias
  • suggested 76 % decrease in clinical deterioration with a high degree of certainty due to low risk of bias
  • suggested 80 % decrease in hospitalization with a high degree of certainty due to low risk of bias
Analysis of final Day 29 data from COMET-ICE confirms sotrovimab significantly reduces hospitalisation and risk of death in adults with mild-to-moderate COVID-19 who are at high risk of progression to severe disease (press release)
Cov-2069 (Cohort B: positive SARS-CoV-2 RT-qPCR test result), 2021
 
NCT04452318
RCTcasirivimab/imdevimab (Ronapreve)placeboCOVID 19 outpatientssome concern
156/158 conclusif
  • demonstrated 44 % decrease in symptomatic Covid-19 (PE) with a moderate degree of certainty due to some concern in risk of bias
BLAZE-1 phase 2 (combination with etesevimab), 2020
 
NCT04427501
RCTbamlanivimab/etesevimabplaceboCOVID 19 outpatientssome concern
112/156 inconclusive
    decreased SARS-CoV-2 log viral load at day 11 compared with placebo of –0.57 [95% CI, –1.00 to –0.14], P = .01
    BLAZE-1 phase 2 (monotherapy), 2020
     
    NCT04427501
    RCTbamlanivimab monotherapyplaceboCOVID 19 outpatientssome concern
    101/156 inconclusive
      no significant difference in viral load reduction was observed for bamlanivimab monotherapy at any dose
      Cov-2067 Weinreich (1200mg) Cohort 1, 2020
       
      NCT04425629
      RCTcasirivimab/imdevimab (Ronapreve)placeboCOVID 19 outpatientssome concern
      838/840 conclusif
      • demonstrated 71 % decrease in hospitalization or death (PE) with a moderate degree of certainty due to some concern in risk of bias
      press release December 2021 : Currently authorized REGEN-COV® (casirivimab and imdevimab) antibodies have diminished potency versus Omicron
      7 studies excluded by filtering options (6 RCT / 1 OBS)

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).